IDH1 and glioblastoma: In this study, we retain the term “GBM” exclusively for IDH-wildtype tumors, in line with the 2021 WHO criteria, while acknowledging that historical data may include a minor subset of IDH-mutant cases now reclassified as astrocytoma, IDH-mutant.